ADRB2 and neoplasm: Collectively, these findings have identified the β2-AR as a therapeutic target that can potentially be exploited to improve anti-tumor immunity, and to mobilize more effective lymphocytes to blood where they can be readily accessed for the ex vivo manufacture of more potent cell products for cancer therapy.